=
4.3 Hz, NCH ), 4.29−4.05 (m, 18H, OCH ), 3.73−3.64 (m, 31H, ArCH , BrCH , OCH , and OCH ), 3.49−3.41 (m, 6H, OCH ), 1.84
2 2 2 2 2 3 2
13
(t, 2H, J = 7.8 Hz, COCH ), 0.65−0.53 (m, 7H, CH and CH ), -0.13−-0.20 (m, 4H, CH ). C NMR (100 MHz, DMSO-d , 298 K): δ
2 2 3 2 6
1
6
73.1, 150.1, 149.0, 148.94, 148.90, 148.8, 148.7, 143.0, 128.40, 128.35, 128.27, 128.1, 128.0, 127.8, 127.4, 124.2, 115.1, 114.8, 113.0,
9.5, 69.4, 68.6, 68.4, 68.3, 68.0, 62.9, 61.6, 55.47, 49.45, 33.3, 32.6, 32.3, 32.2, 32.1, 32.0, 29.9, 28.4, 27.3, 24.0, 21.8, 13.7. HR-ESI-
+
+
MS: m/z Calcd. for C H Br N NaO [M + Na] 1827.9152, found 1827.9158.
68
83
8
3
14
2
.3 The synthesis of P1
The detailed synthesis procedures for compounds 4-6 were provided in Supporting information.
P1: Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (0.05 g, 0.1 mmol) and [Cu(CH CN) ]PF (0.04 g, 0.1 mmol) were
3
4
6
added to a solution of 6 (0.24 g, 1.0 mmol) and AP5 (1.52 g, 1.0 mmol) in chloroform (20 mL) under argon atmosphere, and the
o
mixture was stirred at 25 C for 12 h (Scheme 3). The resulting solution was concentrated in vacuum, and the crude product was
purified by column chromatography (dichloromethane) to afford the target molecule P1 as a white solid (1.02 g, 0.54 mmol, 54%). Mp
o
1
1
65−167 C. H NMR (300 MHz, DMSO-d , 298 K): δ 8.14 (s, 1H, NCH), 7.12−6.82 (m, 10H, ArH), 5.01 (s, 2H, NCH ), 4.61 (t, 2H,
6 2
J = 4.7 Hz, OCH ), 4.20−4.01 (m, 18H, OCH ), 3.86−3.62 (m, 33H, ArCH , OCH , OCH , and BrCH ), 1.85−1.81 (m, 2H, COCH ),
2
2
2
2
3
2
2
13
0
.62 (brs, 2H, CH ), 0.40 (brt, 3H, J = 7.1 Hz, CH ), 0.27 (brd, 2H, J = 7.3 Hz, CH ), -0.44 (brs, 4H, CH ). C NMR (100 MHz,
2 3 2 2
DMSO-d , 298 K): δ 173.1, 150.4, 149.02, 148.96, 148.9, 148.8, 148.7, 128.34, 128.25, 128.21, 128.12, 128.10, 127.99, 127.97, 127.5,
6
1
5
15.5, 115.0, 114.84, 114.81, 114.68, 114.66, 114.54, 114.53, 114.3, 112.9, 68.62, 68.57, 68.36, 68.29, 68.27, 68.23, 68.1, 68.0, 62.5,
5.3, 49.4, 33.4, 32.6, 32.2, 32.1, 32.0, 31.94, 31.92, 29.4, 28.8, 28.5, 28.4, 28.3, 27.2, 23.9, 21.7, 13.5. HR-ESI-MS: m/z Calcd. for
+
+
C H Br N NaO [M + Na] 1783.8890, found 1783.8904.
66
79
8
3
13
TsCl, TEA
O
NaN3
O
O
HO
N3
HO
OTs
HO
OH
DMF, 50 o
45%
C
DCM
5
4
46%
AP5
COOH
N
3
O
O
DCC, DMAP, DCM
TBTA, Cu(CNCH
3 4 6
) PF
O
O
6
7
5%
54%
O
O
Br
N
N
N
O
O
CH
2
CH
2
4
O
O
Br
P1
Scheme 3. The synthetic route of P1.
2
.4 The synthesis of P3
The detailed synthesis procedures for compounds 7-9 were provided in Supporting information.
P3: Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (0.05 g, 0.1 mmol) and [Cu(CH CN) ]PF (0.04 g, 0.1 mmol) were
3
4
6
added to a solution of 9 (0.24 g, 0.72 mmol) and AP5 (1.52 g, 1.0 mmol) in chloroform (20 mL) under argon atmosphere, and the
o
mixture was stirred at 25 C for 12 h (Scheme 4). The resulting solution was concentrated in vacuo. The crude product was purified by
column chromatography (dichloromethane) to afford the target molecule P3 as a white solid (1.10 g, 0.054 mmol, 54%). Mp 148−149
o
1
C. H NMR (400 MHz, DMSO-d , 298 K): δ 8.18 (s, 1H, NCH), 7.06−6.82 (m, 10H, ArH), 5.05 (s, 2H, NCH ), 4.57 (t, 2H, J = 5.0
6
2
Hz, OCH ), 4.23 (brs, 13H, ArCH , and OCH ), 4.14−4.06 (m, 4H, OCH ), 3.86−3.65 (m, 32H, BrCH , and OCH ), 3.60−3.34 (m, 10H,
2
2
3
2
2
2
OCH ), 2.05 (t, 2H, J = 7.7 Hz, COCH ), 1.09−1.06 (m, 2H, CH ), 0.93−0.88 (m, 2H, CH ), 0.69 (t, 3H, J = 7.2 Hz, CH ), 0.56 (brs,
2
2
2
2
3
1
3
4
1
6
2
H, CH2). C NMR (100 MHz, DMSO-d , 298 K): δ 173.0, 150.0, 149.02, 149.01, 148.96, 148.92, 148.90, 148.84, 148.78, 148.5,
6
43.0, 128.5, 128.4, 128.2, 128.0, 127.9, 127.5, 124.4, 115.18, 115.16, 114.9, 114.8, 114.6, 114.5, 114.3, 113.7, 113.2, 69.7, 69.6,
9.54, 69.46, 68.7, 68.6, 68.44, 68.39, 68.3, 68.0, 62.9, 61.6, 55.5, 49.5, 33.4, 32.6, 32.3, 32.22, 32.16, 32.13, 30.3, 28.7, 28.45, 28.40,
+
+
7.6, 24.1, 21.9, 13.8. HR-ESI-MS: m/z Calcd. for C H Br N NaO [M + Na] 1871.9415, found 1871.9421.
7
0
87
8
3
15
Page 4 of 10